带有潜在治疗标的乳头瘤瘤的组织病理学分类和免疫组织化学特征
Jeong Hwan Park1,2, Su-Jin Shin3, Hyun-Jung Kim4
1Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Journal of pathology and translational medicine
|September 11, 2024
概括
乳头性细胞癌 (pRCC) 呈现异质性. 免疫组织化学分析确定了pRCC子集中的c-MET,p16,c-Myc和STING等潜在的治疗点,建议新的向治疗选择.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 分子生物学分子生物学
背景情况:
- 乳头细胞癌 (pRCC) 是一种异质瘤,需要准确的分类.
- 免疫组织化学评估对于确定pRCC中的治疗点至关重要.
- 了解PRCC异质性是准确的患者护理和治疗策略的关键.
研究的目的:
- 为了评估乳头脏瘤的免疫组织化学特征.
- 为了确定不同pRCC亚型中的潜在治疗点.
- 评估pRCC中特定生物标志物的诊断和治疗价值.
主要方法:
- 对140种乳头脏瘤进行了免疫组织化学研究.
- 使用组织微阵列进行分析.
- 对酸脱酶B,烟酸酸酶,转录因子E3,c-MET,p16,c-Myc,Ki-67,p53和STING进行了研究.
主要成果:
- 根据差异诊断标志物重新分类了五例病例 (3.6%).
- 在经典的PRCC中发现了c-MET表达的增加 (p = .021).
- 与经典的pRCC和逆极性瘤相比,在pRCC (NOS) 中观察到更高的Ki-67扩散指数 (p = .080).
- 识别了具有p16 (4.5%) 和c-Myc (7.1%) 表达的小子集,分别仅在pRCC (NOS) 和经典pRCC中表达.
- 观察到与Ki-67指数增加相关的STING表达 (p = .063).
结论:
- 在pRCC的子集中表现出c-MET,p16,c-MYC和STING的表达.
- 这些子集代表了针对性治疗的潜在候选人.
- 免疫组合化学分析有助于识别pRCC的新疗法策略.
更多相关视频
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
13.5K
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.5K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
